(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder - 26 Internet based Staple Help You Can Trust
- 3How to watch the ‘Wicked: One Wonderful Night’ special — now streaming
- 4Mating injuries may lead scientists to identify dinosaurs’ sex
- 5Home Machine Basics: An Exhaustive Purchasing Guide
- Discovering a sense of harmony: Individual Accounts of Reflection and Care
- Compassion and Association: Building Significant Connections
- Vote In favor of Your Number one Kind Of Food Conveyance Administration
- Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- What's the Fate of 5G Innovation?
- Russia accidentally destroys its only way of sending astronauts to space
- 2024 Moving Styles for Kitchen Redesigns
- Charli xcx recorded original songs for 'Wuthering Heights' — what to know about the new album for Margot Robbie's film
- This Week In Space podcast: Episode 186 — Snow on the Moon?
